Rate My Professor Bradley Maron

Dr. Maron's research specializes in precision medicine, network medicine, and computational data analysis, with a focus on redox biochemistry and the pathobiological mechanisms of complex cardiovascular diseases, particularly pulmonary hypertension. He has led international collaborative projects that contributed to the revised definition of pulmonary hypertension now used in clinical practice. As principal investigator and co-principal investigator on NIH-funded studies, including “Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension” and “Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension,” his laboratory employs multi-omics technologies. Dr. Maron is the author or co-author of more than 230 scientific publications in premier journals such as Circulation, The Lancet, and Nature Medicine. Notable publications include “Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis” (The Lancet, 2017), “Genetic misdiagnoses and the potential for health disparities” (New England Journal of Medicine, 2016), and “Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension” (The Lancet Respiratory Medicine, 2020). He is co-inventor on several patents and is incoming Editor-in-Chief of Circulation. Elected to the American Society of Clinical Investigation in 2021, he has received numerous awards for his research, clinical skills, and teaching contributions.